Home > Insider Trading > Filing (0001209191-16-125663)

Filing Details

Accession Number:: 0001209191-16-125663
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-06-03 16:36:27
Reporting Period:: 2016-06-01

Filing Date:: 2016-06-03
Accepted Time:: 2016-06-03 16:36:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
893949	Mednax Inc.	MD	Services-Hospitals (8060)	263667538

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1542492	D Michael Stanley	1301 Concord Terrace Sunrise FL 33323	President, Clinical Services	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-06-01	12,135	$0.00	49,266	No	4	A	Direct
Common Stock	Disposition	2016-06-01	14,778	$67.78	35,247	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 3,034 additional shares based on the achievement of certain performance-based criteria for the period from April 1, 2016 through March 31, 2017. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three equal installments on June 1, 2017, June 1, 2018 and June 1, 2019.
Sales made pursuant to Reporting Person's 105b-1 trading plan.
Sales of shares were made in thirty-seven separate transactions with prices ranging from $67.56 to $67.95 for a weighted average sales price of $67.7838.
Includes 759 restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with achievement in excess of target of specified performance-based criteria for the performance period from April 1, 2015 through March 31, 2016, which restricted shares were not previously reported. The additional restricted shares vest in three equal installments on June 1, 2016, June 1, 2017 and June 1, 2018, subject to continued employment.